Soluble epoxide hydrolase inhibitors and cardiovascular diseases

Zhen He Wang, Benjamin B. Davis, De Qian Jiang, Ting Ting Zhao, Dan Yan Xu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases. Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemiareperfusion injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release bradykinin via an EET-mediated STAT3 signaling pathway to elicit tolerance to ischemia. Summary: Inhibition of sEH has been shown to improve several aspects of cardiovascular diseases, including inflammation, hypertension, cardiac hypertrophy and atherosclerosis. For this reason, sEHIs are promising new pharmaceutical for the treatment of cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalCurrent Vascular Pharmacology
Volume11
Issue number1
StatePublished - 2013

Fingerprint

Epoxide Hydrolases
Cardiovascular Diseases
Anti-Inflammatory Agents
Cardiomegaly
Atherosclerosis
Hypertension
Bradykinin
Reperfusion Injury
Blood Vessels
Ischemia
Inflammation
Acids
Wounds and Injuries
Pharmaceutical Preparations

Keywords

  • Cardiovascular diseases
  • Epoxyeicosatrienoic acids
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Wang, Z. H., Davis, B. B., Jiang, D. Q., Zhao, T. T., & Xu, D. Y. (2013). Soluble epoxide hydrolase inhibitors and cardiovascular diseases. Current Vascular Pharmacology, 11(1), 105-111.

Soluble epoxide hydrolase inhibitors and cardiovascular diseases. / Wang, Zhen He; Davis, Benjamin B.; Jiang, De Qian; Zhao, Ting Ting; Xu, Dan Yan.

In: Current Vascular Pharmacology, Vol. 11, No. 1, 2013, p. 105-111.

Research output: Contribution to journalArticle

Wang, ZH, Davis, BB, Jiang, DQ, Zhao, TT & Xu, DY 2013, 'Soluble epoxide hydrolase inhibitors and cardiovascular diseases', Current Vascular Pharmacology, vol. 11, no. 1, pp. 105-111.
Wang ZH, Davis BB, Jiang DQ, Zhao TT, Xu DY. Soluble epoxide hydrolase inhibitors and cardiovascular diseases. Current Vascular Pharmacology. 2013;11(1):105-111.
Wang, Zhen He ; Davis, Benjamin B. ; Jiang, De Qian ; Zhao, Ting Ting ; Xu, Dan Yan. / Soluble epoxide hydrolase inhibitors and cardiovascular diseases. In: Current Vascular Pharmacology. 2013 ; Vol. 11, No. 1. pp. 105-111.
@article{ef8dca7c48344b93b2999d6c110f1f84,
title = "Soluble epoxide hydrolase inhibitors and cardiovascular diseases",
abstract = "Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases. Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemiareperfusion injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release bradykinin via an EET-mediated STAT3 signaling pathway to elicit tolerance to ischemia. Summary: Inhibition of sEH has been shown to improve several aspects of cardiovascular diseases, including inflammation, hypertension, cardiac hypertrophy and atherosclerosis. For this reason, sEHIs are promising new pharmaceutical for the treatment of cardiovascular diseases.",
keywords = "Cardiovascular diseases, Epoxyeicosatrienoic acids, Soluble epoxide hydrolase",
author = "Wang, {Zhen He} and Davis, {Benjamin B.} and Jiang, {De Qian} and Zhao, {Ting Ting} and Xu, {Dan Yan}",
year = "2013",
language = "English (US)",
volume = "11",
pages = "105--111",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Soluble epoxide hydrolase inhibitors and cardiovascular diseases

AU - Wang, Zhen He

AU - Davis, Benjamin B.

AU - Jiang, De Qian

AU - Zhao, Ting Ting

AU - Xu, Dan Yan

PY - 2013

Y1 - 2013

N2 - Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases. Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemiareperfusion injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release bradykinin via an EET-mediated STAT3 signaling pathway to elicit tolerance to ischemia. Summary: Inhibition of sEH has been shown to improve several aspects of cardiovascular diseases, including inflammation, hypertension, cardiac hypertrophy and atherosclerosis. For this reason, sEHIs are promising new pharmaceutical for the treatment of cardiovascular diseases.

AB - Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases. Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemiareperfusion injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release bradykinin via an EET-mediated STAT3 signaling pathway to elicit tolerance to ischemia. Summary: Inhibition of sEH has been shown to improve several aspects of cardiovascular diseases, including inflammation, hypertension, cardiac hypertrophy and atherosclerosis. For this reason, sEHIs are promising new pharmaceutical for the treatment of cardiovascular diseases.

KW - Cardiovascular diseases

KW - Epoxyeicosatrienoic acids

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84873202544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873202544&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 105

EP - 111

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 1

ER -